Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Cagrilintide 10mg Peptides for Research 99% Purity Certified Mazdutide vs Survodutide Weight Loss Peptide Comparison GLP 1 based therapies for diabetes, obesity and beyond Nature Reviews Drug Discovery